Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Yumanity Therapeutics, Inc.

http://www.yumanity.com/

Latest From Yumanity Therapeutics, Inc.

Yumanity Merges With Proteostasis To Accelerate Parkinson’s Therapy

Yumanity goes public by merging with Proteostasis; it is accelerating its Parkinson’s program because of mouse model data showing disease-modifying potential. Proteostasis will out-license its CF assets.

Deals Business Strategies

Cerevel Goes Public In SPAC Merger To Fund Neuroscience Programs

Deal Snapshot: The $445m Cerevel gains will help as it plans to have at least six programs in the clinic within the next year. CEO Tony Coles will head up a public firm for the first time since Amgen bought Onyx. 

Deals M & A

Merck Warned Of Q2 Slump, But How Far Did Revenue Fall?

The company previously cut 2020 revenue expectations by $2.5bn, including $1.7bn for pharma products. Keytruda’s dominance and portfolio diversification also may dominate second quarter call.

Sales & Earnings Business Strategies

10 Non-COVID News Updates To Listen For In Second Quarter Reporting

The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.

Sales & Earnings Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
  • Other Names / Subsidiaries
    • Proteostasis Therapeutics, Inc.
UsernamePublicRestriction

Register